Wall Street Zen Upgrades Lucid Diagnostics (NASDAQ:LUCD) to “Hold”

Lucid Diagnostics (NASDAQ:LUCD) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a report released on Saturday.

Other equities analysts have also recently issued research reports about the company. Ascendiant Capital Markets boosted their price objective on Lucid Diagnostics from $7.50 to $7.75 and gave the company a “buy” rating in a report on Friday, June 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.00 target price on shares of Lucid Diagnostics in a report on Thursday, May 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $3.55.

Lucid Diagnostics Price Performance

NASDAQ:LUCD opened at $1.02 on Friday. Lucid Diagnostics has a 1 year low of $0.73 and a 1 year high of $1.80. The stock’s 50 day simple moving average is $1.12 and its two-hundred day simple moving average is $1.26. The company has a market cap of $110.65 million, a price-to-earnings ratio of -0.86 and a beta of 1.21.

Institutional Trading of Lucid Diagnostics

A number of hedge funds have recently modified their holdings of LUCD. LPL Financial LLC boosted its stake in shares of Lucid Diagnostics by 29.1% in the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after buying an additional 12,035 shares during the last quarter. Geode Capital Management LLC boosted its position in Lucid Diagnostics by 30.9% during the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock worth $229,000 after purchasing an additional 65,964 shares in the last quarter. Lido Advisors LLC boosted its position in Lucid Diagnostics by 40.0% during the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after purchasing an additional 40,000 shares in the last quarter. Citadel Advisors LLC purchased a new position in Lucid Diagnostics during the fourth quarter worth approximately $98,000. Finally, Sunbelt Securities Inc. purchased a new position in Lucid Diagnostics during the fourth quarter worth approximately $67,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.